ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ABBV AbbVie Inc

144.15
0.74 (0.52%)
Dec 04 2023 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,845,467
Bid Price
Ask Price
News -
Day High 145.49

Low
130.9601

52 Week Range

High
168.11

Day Low 143.27
Company Name Stock Ticker Symbol Market Type
AbbVie Inc ABBV NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.74 0.52% 144.15 18:15:24
Open Price Low Price High Price Close Price Prev Close
143.37 143.27 145.49 144.15 143.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
67,306 4,845,467 $ 144.31 $ 699,269,548 - 130.9601 - 168.11
Last Trade Time Type Quantity Stock Price Currency
19:59:06 1 $ 144.00 USD

AbbVie (ABBV) Options Flow Summary

Overall Flow

Bullish

Net Premium

915k

Calls / Puts

800.00%

Buys / Sells

68.42%

OTM / ITM

157.14%

Sweeps Ratio

0.03%

AbbVie Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
254.5B 1.77B - 58.05B 11.84B 6.70 21.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

AbbVie News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ABBV Message Board. Create One! See More Posts on ABBV Message Board See More Message Board Posts

Historical ABBV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week138.64145.49137.65140.615,813,0165.513.97%
1 Month141.46145.49135.85139.425,399,6632.691.9%
3 Months148.61154.88135.85144.714,916,250-4.46-3.0%
6 Months137.21154.88130.9601143.235,066,9726.945.06%
1 Year162.89168.11130.9601148.445,458,240-18.74-11.5%
3 Years105.15175.91101.5478133.926,293,12939.0037.09%
5 Years93.916175.9162.55109.527,202,21050.2353.49%

AbbVie Description

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Your Recent History

Delayed Upgrade Clock